FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385724800> ?p ?o ?g. }

• W4385724800 abstract "What is this summary about? This is a plain language summary of an article published in the journal Advances in Therapy. In 2020, the US Food and Drug Administration (also called the FDA) approved a medicine called vibegron to treat overactive bladder, also called OAB. The key results used to approve vibegron were from the EMPOWUR study. In the EMPOWUR study, participants who took vibegron had fewer urination episodes, urgency episodes, and bladder leaks each day than those who took a pill containing no medicine, called a placebo. At the end of the study, participants also rated how much their overactive bladder symptoms changed overall during EMPOWUR by responding to a survey. Many participants rated their overactive bladder symptoms as improved overall. This study asked if improvements in the number of urination episodes, urgency episodes, and bladder leaks caused by urgency were associated with feeling better overall. This study also looked at how many participants in the EMPOWUR study had improvements in the number of urination episodes, urgency episodes, and bladder leaks that were big enough to matter. A separate group of people with overactive bladder were asked about the magnitude of improvements that would be important to them. This group had not participated in the EMPOWUR study. What were the results? EMPOWUR participants who reported that taking medicine resulted in their overactive bladder symptoms getting better overall also generally reported fewer daily urinations, urgency episodes, and bladder leaks after treatment. Many had changes in their symptoms that were meaningful. Meaningful was defined for each symptom as: at least 15% fewer urinations, 50% fewer urgency episodes, and 75% fewer bladder leaks. Participants who received vibegron had meaningful reductions in the daily number of episodes of urination, urgency, and bladder leaks more often than those who received the placebo (pill with no active medicine). People with overactive bladder who did not participate in the study were interviewed and said that improvements to those symptoms, similar to those seen in the EMPOWUR study, would be important to them. What do the results mean? This study suggests that the results we measured in the EMPOWUR study may also reflect changes in overactive bladder symptoms that are big enough to be important to people with overactive bladder. Many participants who took vibegron in the EMPOWUR study felt that it helped to improve their individual overactive bladder symptoms. This may also help improve quality of life of participants. Clinical Trial Registration: NCT03492281 (ClinicalTrials.gov)." @default.
• W4385724800 created "2023-08-11" @default.
• W4385724800 creator A5027536929 @default.
• W4385724800 creator A5033252090 @default.
• W4385724800 creator A5047530781 @default.
• W4385724800 creator A5053685634 @default.
• W4385724800 creator A5083628345 @default.
• W4385724800 creator A5092755817 @default.
• W4385724800 date "2023-09-01" @default.
• W4385724800 modified "2023-09-27" @default.
• W4385724800 title "Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?" @default.
• W4385724800 doi "https://doi.org/10.57264/cer-2023-0049" @default.
• W4385724800 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37586052" @default.
• W4385724800 hasPublicationYear "2023" @default.
• W4385724800 type Work @default.
• W4385724800 citedByCount "0" @default.
• W4385724800 crossrefType "journal-article" @default.
• W4385724800 hasAuthorship W4385724800A5027536929 @default.
• W4385724800 hasAuthorship W4385724800A5033252090 @default.
• W4385724800 hasAuthorship W4385724800A5047530781 @default.
• W4385724800 hasAuthorship W4385724800A5053685634 @default.
• W4385724800 hasAuthorship W4385724800A5083628345 @default.
• W4385724800 hasAuthorship W4385724800A5092755817 @default.
• W4385724800 hasBestOaLocation W43857248001 @default.
• W4385724800 hasConcept C126322002 @default.
• W4385724800 hasConcept C126894567 @default.
• W4385724800 hasConcept C142724271 @default.
• W4385724800 hasConcept C159110408 @default.
• W4385724800 hasConcept C175768497 @default.
• W4385724800 hasConcept C204787440 @default.
• W4385724800 hasConcept C27081682 @default.
• W4385724800 hasConcept C2778941218 @default.
• W4385724800 hasConcept C71924100 @default.
• W4385724800 hasConcept C77411442 @default.
• W4385724800 hasConcept C81603835 @default.
• W4385724800 hasConceptScore W4385724800C126322002 @default.
• W4385724800 hasConceptScore W4385724800C126894567 @default.
• W4385724800 hasConceptScore W4385724800C142724271 @default.
• W4385724800 hasConceptScore W4385724800C159110408 @default.
• W4385724800 hasConceptScore W4385724800C175768497 @default.
• W4385724800 hasConceptScore W4385724800C204787440 @default.
• W4385724800 hasConceptScore W4385724800C27081682 @default.
• W4385724800 hasConceptScore W4385724800C2778941218 @default.
• W4385724800 hasConceptScore W4385724800C71924100 @default.
• W4385724800 hasConceptScore W4385724800C77411442 @default.
• W4385724800 hasConceptScore W4385724800C81603835 @default.
• W4385724800 hasIssue "9" @default.
• W4385724800 hasLocation W43857248001 @default.
• W4385724800 hasLocation W43857248002 @default.
• W4385724800 hasOpenAccess W4385724800 @default.
• W4385724800 hasPrimaryLocation W43857248001 @default.
• W4385724800 hasRelatedWork W1972451622 @default.
• W4385724800 hasRelatedWork W2002325903 @default.
• W4385724800 hasRelatedWork W2071699168 @default.
• W4385724800 hasRelatedWork W2381658177 @default.
• W4385724800 hasRelatedWork W2412523252 @default.
• W4385724800 hasRelatedWork W2605515582 @default.
• W4385724800 hasRelatedWork W2606611151 @default.
• W4385724800 hasRelatedWork W2784783440 @default.
• W4385724800 hasRelatedWork W3212015874 @default.
• W4385724800 hasRelatedWork W4206166447 @default.
• W4385724800 hasVolume "12" @default.
• W4385724800 isParatext "false" @default.
• W4385724800 isRetracted "false" @default.
• W4385724800 workType "article" @default.